USPTO serial 88820915
MMX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 14, 2021
- Examiner
- CANTOR, JILLIAN REDDING
- Law office
- TMO LAW OFFICE 137
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with MMX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Pickerill
John Pickerill Fredrikson & Byron, P.A.200 South 6th Street, Suite 4000Minneapolis, MN 55402UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Contrast media for use with medical equipment or in medical imaging, namely, endoscopy, x-ray, ultrasound, MRI, PET and CT equipment; Diagnostic agents and reagents for medical use; Diagnostic preparations for medical purposes; Pharmaceutical preparations and substances, namely, prescription medicines in the form of pills, tablets, capsules, caplets, and liquid drops for the treatment of gastrointestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders, gastrointestinal diseases or digestive system disorders; Pharmaceutical preparations for the treatment or prevention of IBS (irritable bowel syndrome); Non-prescription medicines, namely, pills, tablets, capsules, caplets, and liquid drops for the treatment of gastrointestinal disorders; Pharmaceutical preparations for treating gastrointestinal disorders; diagnostic agents, preparations and substances for medical purposes, namely, the visual enhancing or visualization of polyps, adenomas, carcinomas, early stage cancers and other lesions in the colon for patients undergoing endoscopy, colonoscopy, sigmoidoscopy, anoscopy, rectoscopy and proctoscopy; contrast media for medical and surgical use; contrast media for use with gastroscopic, endoscopic, colonoscopic, sigmoidoscopic, anoscopic, rectoscopic and proctoscopic equipment; pharmaceutical preparations to aid the detection, diagnosis, prevention or treatment of gastroenterological diseases; pharmaceutical preparations for use in gastroenterology, endoscopy, colonoscopy, sigmoidoscopy, anoscopy, rectoscopy and proctoscopy; pharmaceutical preparations containing methylene blue or dye for visual enhancing or visualization during endoscopic procedures; pharmaceutical preparations containing methylene blue or dye for pharmaceutical, medical and surgical purposes, namely, detection, diagnosis, prevention or treatment of gastroenterological diseases; Medical and surgical dyes, namely, methylene blue dye; Medical dyes for pharmaceutical and diagnostic purposes, namely, the visual enhancing or visualization of polyps, adenomas, carcinomas, early stage cancers and other lesions in the colon for patients undergoing endoscopy, colonoscopy, sigmoidoscopy, anoscopy, rectoscopy and proctoscopy; pharmaceutical preparations for the diagnosis, prevention or treatment of ulcerative colitis or inflammatory bowel diseases; pharmaceutical preparations for the treatment of fertility, reproductive health, hematology, urology, gynecology, obstetrics, endocrinology, oncology, renalology, immunology and inflammatory diseases, disorders and conditions; pharmaceutical preparations for colon and digestive system health and regulation, for improving energy levels or for maintaining and improving mucous levels and the mucosal lining of the intestines and colon; diarrhea medication; Anti-nausea medication; antiemetic preparations; antibiotic preparations; pharmaceutical preparations for the treatment or prevention of travelers' diarrhea, diarrhea, diverticular disease, diverticulitis or infectious colitis | ACTIVE | — |
| 044 | Providing health care information by the internet; pharmaceutical advice; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cosmo Technologies Ltd
- Other trademarks owned by Cosmo Technologies Ltd
- Other trademarks owned by Cosmo Technologies Ltd
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named MMX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 14, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 14, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 29, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 29, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 9, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 27, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 11, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 11, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 7, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Mar 19, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 19, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 19, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 12, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 12, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 10, 2021 | ALIE | ASSIGNED TO LIE | — |
| Dec 8, 2020 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Dec 7, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 7, 2020 | PETG | PETITION TO REVIVE-GRANTED | — |
| Dec 7, 2020 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Dec 4, 2020 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 4, 2020 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 19, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 19, 2020 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Nov 19, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 19, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 17, 2020 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Nov 17, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 17, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 20, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| May 11, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 11, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 11, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 11, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 11, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 10, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 7, 2020 | NWAP | NEW APPLICATION ENTERED | — |